GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Michael A, Nauck,; Daniel R, Quast,; Jakob, Wefers,; Juris J, Meier,

doi:10.1016/j.molmet.2020.101102

Public

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Published in Molecular metabolism • Apr 1, 2021

Authors:

Nauck, Michael A

Quast, Daniel R

Wefers, Jakob

Abstract

BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short in...

Subject

Albiglutide

Body weight

Cardiovascular disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!